What indicators should be reviewed regularly while taking Bikken Pronol Tablets (Bituvi) to ensure medication safety?

While taking Biktarvy tablets (Biktarvy), regular review of various indicators is crucial to ensure the safety and efficacy of the medication. First, hematological indicators need to be monitored, including complete blood cell count (white blood cells, red blood cells, platelets) and liver function indicators (ALT, AST, total bilirubin). This can detect liver function abnormalities or blood cell production abnormalities that may be caused by drugs early and avoid serious adverse reactions. The frequency of reexamination is generally once every 4 weeks in the early stage of treatment, and can be appropriately extended after the blood is stable.

Secondly, renal function indicators should be monitored regularly. Although the tenofovir disoproxilate (TAF) in Bikerenprenol tablets has low nephrotoxicity, it may still affect the glomerular filtration rate (eGFR) and serum creatinine levels. Especially patients with chronic kidney disease, diabetes or hypertension need to pay more attention to changes in renal function so that they can adjust their medication dosage or take protective measures when necessary.

Third, attention needs to be paid toHIV virological indicators and immune function. Regular detection of plasmaHIV-1 RNA load and CD4+ lymphocyte count is an important basis for evaluating antiviral efficacy and immune recovery. By comparing the data before and after treatment, doctors can determine whether the drug's efficacy meets expectations and whether the dose needs to be adjusted or combined with other antiviral drugs to ensure that the virus is effectively suppressed and the risk of drug resistance is reduced.

In addition, for patients with comorbidities, cardiovascular indicators, blood lipids, and blood sugar should also be monitored. Some patients may experience mild elevation of blood lipids or increased cardiovascular risk after long-term use of Biktarvy. Regular follow-up can detect abnormalities in time and guide lifestyle intervention or drug intervention. At the same time, patients should report any abnormal symptoms at any time, such as fatigue, jaundice, kidney discomfort, etc., so that doctors can make comprehensive judgments and ensure the safety and efficacy of long-term medication.

Reference materials:https://www.drugs.com/